298. Hereditary pancreatitis Clinical trials / Disease details
Clinical trials : 95 / Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000037002 | 2020-10-01 | 2020-08-26 | Differential diagnosis of pancreatic cancer and chronic pancreatitis with serum miR-25 | A prospective study of serum miR-25 detection in differential diagnosis of pancreatic cancer and chronic pancreatitis | pancreatic cancer | Gold Standard:Pancreatic cancer: pancreatic ductal adenocarcinoma originating from pancreatic ductal epithelium was confirmed by pathological examination (operative biopsy, puncture biopsy, cytological examination). Chronic pancreatitis: Clinically diagnosed as chronic pancreatitis, and no evidence to support the diagnosis of pancreatic cancer.;Index test:Serum miR-25; | The First Affiliated Hospital of the Naval Medical University of the Chinese People's Liberation Army | NULL | Pending | 18 | 75 | Both | Target condition:150;Difficult condition:150 | China |